News Breaks
June 8, 2012
08:43 EDT SGEN
Seattle Genetics price target raised to $25 from $20 at Needham
Based on data presented at ASCO from ongoing Adcetris clinical trials, Needham believes Seattle Genetics may succeed in adding retreatment to the drug's label later this year. The firm raised its price target on the stock to $25, citing its view that Adcetris may fill an important role in oncology, and keeps a Buy rating on the stock. :theflyonthewall.com